FFP’s with Complete Screening (One Bag) at Chughtai Lab

FFP’s with Complete Screening (One Bag) at Chughtai Lab

Fresh Frozen Plasma (FFP) is a cornerstone of modern transfusion medicine and critical care. It is the liquid portion of whole blood that is separated and frozen within eight hours of collection to preserve its vital, labile coagulation factors. The clinical utility of FFP lies in its rich concentration of clotting proteins, including Factor V, Factor VIII, fibrinogen, antithrombin, and other essential plasma proteins. At Chughtai Lab, Pakistan’s premier diagnostic and blood banking network, FFP’s with Complete Screening (One Bag) represents a highly secure, thoroughly evaluated therapeutic product designed to restore hemostasis in patients facing life-threatening bleeding or severe coagulopathies.

The term “Complete Screening” refers to the rigorous, state-of-the-art testing protocols applied to every single bag of plasma. This screening process ensures that the blood product is free from major transfusion-transmitted infections (TTIs), including Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV-1 and HIV-2), Syphilis, and Malaria. By utilizing advanced chemiluminescence immunoassay (CLIA) and molecular testing technologies, Chughtai Lab guarantees the highest level of safety for recipients across its extensive network of hospitals and collection centers in Lahore, Karachi, Islamabad, and other major cities in Pakistan.

The clinical importance of this product cannot be overstated. When a patient suffers from massive hemorrhage, liver failure, or disseminated intravascular coagulation (DIC), their body rapidly depletes its natural clotting factors. Transfusing a bag of completely screened FFP provides an immediate, concentrated source of these essential proteins, helping to stabilize the patient, control active bleeding, and facilitate safe surgical interventions. The diagnostic value of the screening process lies in its ability to eliminate the risk of infectious disease transmission, providing clinicians with absolute confidence during critical therapeutic procedures.

Clinical Procedure: What to Expect

Patient Preparation

For the recipient of FFP’s with Complete Screening (One Bag) at Chughtai Lab, preparation is focused on clinical safety and compatibility. The following steps are essential:

• Blood Grouping and Cross-matching: A fresh blood sample must be collected from the recipient to determine their ABO and Rh blood group. FFP must be compatible with the recipient’s red blood cells to prevent hemolytic transfusion reactions.
• Informed Consent: The attending physician or clinical staff must explain the benefits, risks, and alternatives of the plasma transfusion, and obtain signed informed consent from the patient or their legal guardian.
• Intravenous Access: A patent, large-bore intravenous (IV) cannula (typically 18G or 20G) must be established to facilitate the smooth infusion of the viscous plasma product.
• Pre-transfusion Vitals: Baseline vital signs, including temperature, blood pressure, heart rate, and respiratory rate, must be recorded immediately before starting the transfusion.
• Medication Review: Inform the healthcare team of all current medications, especially anticoagulants or antiplatelet drugs, which may influence the clinical response to FFP.

During the Procedure

The administration of FFP is a highly regulated clinical process performed by trained nursing staff under medical supervision:

• Product Thawing: The frozen FFP bag is retrieved from Chughtai Lab’s temperature-controlled storage (-18°C or colder) and thawed using a specialized, FDA-approved temperature-controlled water bath or dry-tempering system at 30°C to 37°C. This preserves the functional integrity of the labile clotting factors.
• Double Verification: Before infusion, two qualified healthcare professionals must verify the patient’s identity, blood group, bag number, expiration date, and the compatibility report against the patient’s wristband.
• Infusion Set: FFP is administered through a standard blood administration set equipped with a 170-to-260-micron filter to trap any microaggregates or fibrin clots that may have formed during storage or thawing.
• Monitoring: The transfusion is initiated slowly for the first 15 minutes while closely monitoring the patient for signs of acute transfusion reactions, such as fever, chills, urticaria, dyspnea, or hypotension. If tolerated, the infusion rate is adjusted to complete the bag within 30 to 60 minutes.
• Post-Transfusion Assessment: Once the transfusion is complete, vital signs are recorded again, and the patient is monitored for delayed reactions. Post-transfusion coagulation profiles (such as PT, APTT, and INR) are typically ordered to assess the therapeutic efficacy of the transfusion.

When is a FFP’s with Complete Screening (One Bag) Performed?

Management of Active Bleeding in Coagulopathy

Physicians request FFP’s with Complete Screening when a patient is experiencing active, clinically significant bleeding associated with multiple coagulation factor deficiencies. This is common in patients with severe liver disease, where the synthesis of clotting factors is severely impaired. By transfusing FFP, clinicians can rapidly replenish the depleted proteins, promote clot formation, and arrest hemorrhage in critical anatomical sites.

Preoperative Correction of Coagulation Factor Deficiencies

Prior to undergoing invasive surgical procedures, patients with known coagulopathies or prolonged clotting times (such as an elevated International Normalized Ratio, or INR) require prophylactic correction. Transfusing FFP before surgery minimizes the risk of intraoperative and postoperative bleeding, ensuring a safer surgical field and reducing the need for emergency whole-blood transfusions during the procedure.

Treatment of Disseminated Intravascular Coagulation (DIC)

Disseminated Intravascular Coagulation is a complex, life-threatening systemic process characterized by widespread microvascular thrombosis and subsequent consumption of platelets and clotting factors. In the presence of active bleeding or high bleeding risk, FFP is administered as part of a comprehensive resuscitation strategy to replace consumed coagulation factors and restore hemostatic balance.

Rapid Reversal of Warfarin (Vitamin K Antagonist) Therapy

Patients on warfarin therapy who present with life-threatening bleeding or require emergency surgery cannot wait for the slow action of oral or intravenous Vitamin K. FFP’s with Complete Screening provides an immediate source of the functional Vitamin K-dependent clotting factors (Factors II, VII, IX, and X), rapidly reversing the anticoagulant effect and stabilizing the patient’s coagulation profile.

Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura (TTP)

In patients diagnosed with Thrombotic Thrombocytopenic Purpura (TTP), therapeutic plasma exchange (plasmapheresis) is a life-saving intervention. FFP is used as the replacement fluid during this procedure. It serves a dual purpose: it removes the patient’s autoantibodies against the ADAMTS13 enzyme and replenishes the missing ADAMTS13 metalloproteinase, thereby halting the microangiopathic hemolytic process.

What Does a FFP’s with Complete Screening (One Bag) Detect?

The “Complete Screening” protocol applied to each bag of FFP at Chughtai Lab is designed to detect and rule out the presence of infectious agents and verify the quality of the blood product. The screening panel and quality parameters include:

• Hepatitis B Surface Antigen (HBsAg): Detects active Hepatitis B infection in the donor.
• Hepatitis C Virus Antibodies (Anti-HCV): Identifies exposure to or chronic infection with the Hepatitis C virus.
• HIV-1 and HIV-2 Antibodies/Antigens: Screens for the presence of Human Immunodeficiency Virus to prevent transfusion-transmitted AIDS.
• Syphilis Antibodies (VDRL/TPHA): Detects Treponema pallidum, the causative agent of syphilis.
• Malaria Parasites: Screens for Plasmodium species to prevent the transmission of malaria.
• ABO Blood Grouping: Confirms the specific blood group (A, B, AB, or O) of the donor plasma.
• Rh Factor Typing: Identifies the presence or absence of the D antigen (Rh-positive or Rh-negative).
• Fibrinogen Levels: Measures the concentration of fibrinogen to ensure adequate therapeutic potency.
• Factor VIII Activity: Assesses the functional level of this labile clotting factor, which serves as a surrogate marker for overall plasma quality.
• Total Protein Content: Verifies that the plasma contains normal physiological levels of albumin and globulins.
• Visual Inspection (Color): Ensures the plasma is straw-colored and free from excessive hemolysis (red tint) or lipemia (milky appearance).
• Sterility Testing: Confirms the absence of bacterial contamination in the prepared blood component.
• Volume Verification: Ensures the bag contains the standard therapeutic volume (typically 200 to 250 mL).
• pH Level: Monitors the acid-base balance of the stored plasma to ensure physiological compatibility.
• Antithrombin III Levels: Verifies the presence of natural anticoagulants that help regulate the clotting cascade.
• Protein C and Protein S Levels: Confirms the presence of these essential regulatory proteins.
• Atypical Antibodies: Screens the donor plasma for unexpected red cell antibodies that could cause adverse reactions in the recipient.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that blood products and coagulation therapies are often required in urgent or emergency clinical scenarios. The preparation, thawing, and cross-matching of FFP’s with Complete Screening (One Bag) are prioritized to ensure rapid delivery to the bedside. Under standard conditions, once the recipient’s blood sample is received for cross-matching, the compatible and thawed FFP bag is typically ready for release within a few hours.

The complete screening reports of the donor bag are meticulously documented and archived in our laboratory information system. Clinicians and authorized hospital staff can access these safety records and compatibility reports instantly through the Chughtai Lab online portal and mobile application. This seamless digital integration ensures that critical safety data is available at the point of care when every minute counts.

FFP’s with Complete Screening (One Bag) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Hepatitis B Surface Antigen (HBsAg)	Non-Reactive (Negative)	Reactive (Positive) – Product discarded
Hepatitis C Antibodies (Anti-HCV)	Non-Reactive (Negative)	Reactive (Positive) – Product discarded
HIV-1 & HIV-2 Antibodies/Antigens	Non-Reactive (Negative)	Reactive (Positive) – Product discarded
Syphilis (VDRL/TPHA)	Non-Reactive (Negative)	Reactive (Positive) – Product discarded
Malaria Screening	Negative (No parasites detected)	Positive – Product discarded
ABO/Rh Compatibility	Compatible with recipient’s red blood cells	Incompatible – Risk of acute hemolytic reaction
Fibrinogen Level	> 150 mg/dL	< 150 mg/dL – Reduced therapeutic efficacy
Factor VIII Activity	> 0.7 IU/mL (70% activity)	< 0.7 IU/mL – Indicates poor preservation of labile factors
Visual Appearance	Clear, straw-colored liquid	Hemolyzed (red), lipemic (milky), or icteric (deep yellow)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for FFP’s with Complete Screening (One Bag)?

• CAP Accreditation: Chughtai Lab is accredited by the College of American Pathologists (CAP), ensuring international gold standards in quality control and patient safety.
• Advanced Blood Banking Technology: We utilize state-of-the-art automated screening platforms and FDA-approved thawing systems to maintain the highest quality of blood components.
• Rigorous Donor Screening: Every donor undergoes a comprehensive medical evaluation and strict screening protocol before blood donation is permitted.
• 24/7 Availability: Our blood bank services and emergency cross-matching are operational round-the-clock, 365 days a year, to support critical patient care.
• Temperature-Controlled Logistics: From collection to storage and transport, we maintain a strict cold chain to preserve the functional activity of labile clotting factors.
• Highly Qualified Pathologists: Our blood bank is supervised by consultant hematologists and transfusion medicine specialists with extensive clinical experience.
• Seamless Digital Access: Patients and clinicians can access compatibility reports and screening certificates instantly via our mobile app and online portal.
• Nationwide Network: With a presence in Lahore, Karachi, Islamabad, and beyond, we ensure timely access to safe blood products across Pakistan.